Our Vaccines business is one of the largest in the world, developing, producing and distributing over 2 million vaccines every day to people across 170 countries. Currently, GSK has the largest vaccines business in Pakistan. As an industry leader GSK is committed to its mission of improving the quality of human life by enabling people to do more, feel better and live longer.

GSK’s vaccines portfolio is one of the largest in the world, producing both pediatric and adult vaccines against a range of infectious diseases. GSK vaccines have been helping protect people from serious disease since the 1950s, when we introduced our first polio vaccine. Over a period of 60 years, GSK has developed more than 30 vaccines, many of which were the first of their kind in the market, including vaccines against rubella, measles, chickenpox, hepatitis B and hepatitis A.

Other global firsts include combination vaccines against diphtheria, tetanus, whooping cough and hepatitis B, hepatitis A and B. In recent years GSK has launched several new innovative vaccines which provide protection against cervical cancer, rotavirus and pneumococcal disease.

Our pipeline of potential new vaccines covers many of the diseases still having a serious impact around the world, including malaria, HIV, TB and Ebola.

In line with our global heritage GSK Vaccines Pakistan has been providing protection against various diseases in Pakistan since 1989 with 18 vaccines registered for the prevention of various vaccine preventable diseases for infants, adolescent & adults.

GSK has distributed more than 251 million doses to approximately 65 million people to provide protection against various vaccine preventable diseases in Pakistan.

Our acquisition of Novartis Vaccines (excluding influenza vaccines) in early 2015 significantly expanded the number of vaccines we produce (now around 40), as well as the number of new vaccines we have in development (17), giving us the broadest portfolio of any vaccines company in the world.

Our marketplace

Vaccination is recognised worldwide as one of the best investments that any government or healthcare organisation can make. In 2012, the WHO and its 194 member’s states published an action plan on vaccination that aims to prevent millions of deaths by 2020.

This involves more equitable access to existing vaccines for people in all communities, the introduction of new and improved vaccines and accelerated research and development for the next generation of vaccines and technologies. Overall, this translates in a growing global demand for vaccines over the next 10-15 years.

Quality and manufacturing

In 2014, we distributed more than 800 million doses of vaccine around the world. These are made in one of our 14 manufacturing sites located around the world. For some of our vaccines, this production process can take up to two years.

On average, each batch of vaccine will have undergone more than 100 quality checks before it is sent out, to ensure the vaccines meet world-class standards. Each of our vaccines is produced to the same quality standard, regardless of where in the world the vaccine will be used.

We are continuously investing in our manufacturing facilities, improving our processes and building partnerships to ensure we meet the global growing needs for high quality vaccines.

Research and collaboration

Scientific advances are central to our ability to innovate, and we continue to invest in the science to discover and develop new vaccines, both to protect against diseases where vaccines are not yet available and to improve on those vaccines that already exist. This research includes our efforts to find new vaccines against malaria, HIV and tuberculosis.

We are also seeking to overcome the challenges of transporting our vaccines to remote communities, where at present many vaccines must be kept at constant low temperatures throughout the supply and transportion process.

We’re currently maintaining over 100 partnerships in R&D alone and have a long track record of collaborating with governments, healthcare providers, regulators, academic institutions, non-governmental organisations, vaccine producers and other key partners to tackle the healthcare challenges of the world’s neediest communities.